Form D · Biotechnology
JW (Cayman) Therapeutics Co. Ltd
Shanghai, F4 · CIK 0001817872
Offering snapshot reported Jul 15, 2020 · SEC filing
- Reported sold
- $106M Offering amount: $106M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 15, 2020 | Initial | $105,548,653 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-371020
Source: Form D, filed Jul 15, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Hans Edgar Bishop | Director |
| Yanling Cao | Director |
| Xin Fu | Executive |
| Xing Gao | Director |
| Harry Lam | Executive |
| Ann Li Lee | Director |
| Yiping James Li | Director, Executive |
| Cheng Liu | Director |
| Jingwen Miao | Director |
| Wenjun Sun | Executive |
| Krishna Viswanadhan | Director |
| Jinyin Wang | Director |
| Yunxia Yang | Director |
| Hongxia Zheng | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4560 Jinke Road, Floor 2, Bldg. 3 Pudong New District
Shanghai, F4, 201210
Shanghai, F4, 201210